Details of the Drug Reposition

General Information of This Drug (ID: DMZ9YWG)

Drug Name	SB 11285 DMZ9YWG

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Melanoma	DIS1RRCY	2C30	Phase 1	[1]
Head-neck squamous cell carcinoma	DISF7P24	2D60.0	Phase 1	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04096638) Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.